Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 525,468 shares, a decline of 19.0% from the December 31st total of 649,057 shares. Based on an average daily trading volume, of 374,723 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.7% of the company’s shares are short sold. Currently, 0.7% of the company’s shares are short sold. Based on an average daily trading volume, of 374,723 shares, the days-to-cover ratio is currently 1.4 days.

Hedge Funds Weigh In On Jyong Biotech

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in shares of Jyong Biotech in the 3rd quarter worth $512,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Jyong Biotech during the 4th quarter valued at approximately $49,000. Finally, BNP Paribas Financial Markets purchased a new position in Jyong Biotech during the third quarter valued at approximately $67,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Jyong Biotech Price Performance

NASDAQ MENS traded down $0.09 during trading hours on Wednesday, hitting $2.10. The company’s stock had a trading volume of 295,429 shares, compared to its average volume of 386,990. The company’s 50 day simple moving average is $10.49 and its two-hundred day simple moving average is $32.42. Jyong Biotech has a 12 month low of $2.04 and a 12 month high of $67.00.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.